Topical treatments are administered to skin or mucous membranes to alleviate a variety of conditions. These treatments broadly encompass creams, foams, gels, lotions and ointments. There are a number of sought-after attributes for conferring desired properties to a topical formulation: rheology control, spreadability, adhesion and diffusion control. Ashland offers high-quality cellulose ethers such as Natrosol™ 250 hydroxyethylcellulose, Klucel™ hydroxypropylcellulose and Aqualon™ sodium carboxymethylcellulose to deliver these properties. Some of the topical film formers offered in our skin-care product lines are also suitable for use in topical applications. Plasdone™ povidone is also a good film former for topical applications. Contact us to learn more about our solutions for topical and transdermal applications.
Over the ensuing 18 months, federal investigators obtained overwhelming evidence implicating Bauman and the five co-conspirators working for him. Bauman was primarily in charge of social media, internet marketing, sales and customer service. Philip Goodwin was the “chemist” in charge of converting raw steroid powder into finished oral and injectable steroid products. Bauman’s fiancee Katie Green was largely responsible handling the money flow in the organization. Robert Medeiros was in charge of shipping product to customers. And Melissa Sclafani helped Bauman launder money through the Wicked Tan tanning salon.
Mr. Gerhart has more than 25 years of experience starting, financing, and building companies based on promising technologies. Prior to founding Patara, he was the President & CEO of Elevation Pharmaceuticals, a San Diego-based biotech he founded in 2008 that developed a new inhaled therapy for patients with severe chronic obstructive pulmonary disease (COPD). After completion of Phase 2 clinical trials, Elevation was acquired in 2012 by Sunovion, a subsidiary of Dainippon Sumitomo Pharma, for up to $430 million. In 2017, the FDA approved this new therapy, marketed as Lonhala™ Magnair™, the first nebulized LAMA for COPD patients. Mr. Gerhart was the President and CEO of Mpex Pharmaceuticals from 2002 to 2007, a company he helped found to discover and develop new antibacterials for the treatment of serious infections including Quinsair®, an inhaled antibiotic, now approved in Europe and Canada for the treatment of cystic fibrosis. Mr. Gerhart is a member of the Board of Trustees at the Sanford Burnham Prebys Medical Discovery Institute and a member of YPO. He earned an MBA degree at Harvard University and a BBA degree at Baylor University.